D
DNLI
Denali Therapeut
24.35
-0.05-0.20%Closed19:52 08/17 EDT
OPEN/PREV CLOSE25.24/24.95
TODAY RANGE24.60-25.29
VOL325.25K
MARKET CAP3.94B
52 WEEK RANGE12.58-27.30
AVG VOL (3M)1.78M
% TURNOVER0.20%
TURNOVER--
P/E (TTM)-8.6954
% RANGE2.77%
EPS(TTM)-2.8377
P/E(FORWARD)-9.6765
P/B4.720
BVPS5.23
DIVIDEND--
P/S7.15
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.73B
SHARES OUTSTANDING159.85M
NEXT EARNINGS11/04-11/09
FREE FLOAT151.07M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·2d ago
Denali Therapeutics: Bullish On Avlayah And Their Prospects
Simply Wall St·4d ago
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report
Simply Wall St·6d ago
Will AVLAYAH’s Launch And Cash Windfall Reshape Denali Therapeutics' (DNLI) Investment Narrative
TipRanks·08/14 02:07
Top Denali Therapeutics Executive Makes Notable Move With Insider Stock Sale
Seeking Alpha·08/13 16:13
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
TipRanks·08/11 11:55
Denali Therapeutics (DNLI) Receives a Buy from J.P. Morgan
Simply Wall St·08/08 02:32
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue
Dow Jones·08/07 23:46
Denali Therapeutics Is Maintained at Buy by UBS
Benzinga·08/07 23:37
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34
NASDAQ·08/07 18:31
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
TipRanks·08/07 13:06
Denali Therapeutics price target raised to $34 from $25 at UBS
TipRanks·08/07 11:55
Denali Therapeutics price target raised to $34 from $31 at Baird
Same Industry
Name/Symbol
Change%
Price